Immunic, Inc. (IMUX) Current Ratio
- Current ratio · latest quarter: Value 5.05×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.05× | Current assets / current liabilities. $157.83M ÷ $31.26M ≈ 5.05× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 157.83M USD | Assets, Current |
| Current obligations | 31.26M USD | Liabilities, Current |
| Cash and equivalents | 155.10M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 12.66M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $157.83M | $31.26M | $155.10M | (m) | (m) | (m) | $12.66M | (m) | 5.05× |
| 2026-03-31 | $188.76M | $38.36M | $186.63M | (m) | (m) | (m) | $11.01M | (m) | 4.92× |
| 2025-12-31 | $22.87M | $30.62M | $15.48M | (m) | (m) | (m) | $10.14M | (m) | 0.75× |
| 2025-09-30 | $39.27M | $30.08M | $35.13M | (m) | (m) | (m) | $7.92M | (m) | 1.31× |
| 2025-06-30 | $59.84M | $27.31M | $55.31M | (m) | (m) | (m) | $7.89M | (m) | 2.19× |
| 2025-03-31 | $18.98M | $25.59M | $14.30M | (m) | (m) | (m) | $6.01M | (m) | 0.74× |
| 2024-12-31 | $39.33M | $22.18M | $35.67M | (m) | (m) | (m) | $7.85M | (m) | 1.77× |
| 2024-09-30 | $63.27M | $23.36M | $59.07M | (m) | (m) | (m) | $6.04M | (m) | 2.71× |
| 2024-06-30 | $84.98M | $22.68M | $79.70M | (m) | (m) | (m) | $7.89M | (m) | 3.75× |
| 2024-03-31 | $102.61M | $20.15M | $97.31M | (m) | (m) | (m) | $6.77M | (m) | 5.09× |
| 2023-12-31 | $52.53M | $24.73M | $46.67M | (m) | (m) | (m) | $5.10M | (m) | 2.12× |
| 2023-09-30 | $65.23M | $17.78M | $59.69M | (m) | (m) | (m) | $3.20M | (m) | 3.67× |
| 2023-06-30 | $86.55M | $18.24M | $77.29M | (m) | (m) | (m) | $4.70M | (m) | 4.74× |
| 2023-03-31 | $106.58M | $16.30M | $92.76M | (m) | (m) | (m) | $5.24M | (m) | 6.54× |
| 2022-12-31 | $125.86M | $13.08M | $106.75M | (m) | (m) | (m) | $4.28M | (m) | 9.62× |
| 2022-09-30 | $86.65M | $11.51M | $72.77M | (m) | (m) | (m) | $4.17M | (m) | 7.53× |
| 2022-06-30 | $104.76M | $10.40M | $88.08M | (m) | (m) | (m) | $4.12M | (m) | 10.07× |
| 2022-03-31 | $115.88M | $11.46M | $95.71M | (m) | (m) | (m) | $3.29M | (m) | 10.11× |
| 2021-12-31 | $104.99M | $11.40M | $86.86M | (m) | (m) | (m) | $3.75M | (m) | 9.21× |
| 2021-09-30 | $122.50M | $10.59M | $110.44M | (m) | (m) | (m) | $3.24M | (m) | 11.57× |
| 2021-06-30 | $101.69M | $14.49M | $87.17M | (m) | (m) | (m) | $4.18M | (m) | 7.02× |
| 2021-03-31 | $120.28M | $16.36M | $114.84M | (m) | (m) | (m) | $10.05M | (m) | 7.35× |
| 2020-12-31 | $133.75M | $8.40M | $127.45M | (m) | (m) | (m) | $3.70M | (m) | 15.93× |
| 2020-09-30 | $137.54M | $8.03M | $133.18M | (m) | (m) | (m) | $3.42M | (m) | 17.13× |
| 2020-06-30 | $53.02M | $7.67M | $48.61M | (m) | (m) | (m) | $1.73M | (m) | 6.91× |
| 2020-03-31 | $23.60M | $6.33M | $18.58M | (m) | (m) | (m) | $1.43M | (m) | 3.73× |
| 2019-12-31 | $32.23M | $7.07M | $29.37M | (m) | (m) | (m) | $2.42M | (m) | 4.56× |
| 2019-09-30 | $34.52M | $7.04M | $30.46M | (m) | (m) | (m) | $3.72M | (m) | 4.91× |
| 2019-06-30 | $39.49M | $3.12M | $36.12M | (m) | (m) | (m) | $1.46M | (m) | 12.65× |
| 2019-03-31 | $9.99M | $1.43M | $9.60M | (m) | (m) | (m) | $184.00K | (m) | 6.97× |
| 2018-12-31 | $13.33M | $1.92M | $13.07M | (m) | (m) | (m) | $1.40M | (m) | 6.94× |
| 2018-09-30 | $19.06M | $5.69M | $17.80M | (m) | (m) | (m) | $1.13M | (m) | 3.35× |
| 2018-06-30 | $32.65M | $8.30M | $31.12M | (m) | (m) | (m) | $1.07M | (m) | 3.93× |
| 2018-03-31 | $44.84M | $9.67M | $43.65M | (m) | (m) | (m) | $893.00K | (m) | 4.64× |
| 2017-12-31 | $58.12M | $10.28M | $56.90M | (m) | (m) | (m) | $1.05M | (m) | 5.65× |
| 2017-09-30 | $67.96M | $8.23M | $66.39M | (m) | (m) | (m) | $981.00K | (m) | 8.25× |
| 2017-06-30 | $78.06M | $7.29M | $76.15M | (m) | (m) | (m) | $1.08M | (m) | 10.71× |
| 2017-03-31 | $88.30M | $6.45M | $86.64M | (m) | (m) | (m) | $1.31M | (m) | 13.69× |
| 2016-12-31 | $61.46M | $5.48M | $59.99M | (m) | (m) | (m) | $780.00K | (m) | 11.22× |
| 2016-09-30 | $69.46M | $4.63M | $68.09M | (m) | (m) | (m) | $1.19M | (m) | 15.00× |
| 2016-06-30 | $75.44M | $4.47M | $73.60M | (m) | (m) | (m) | $887.00K | (m) | 16.86× |
| 2016-03-31 | $79.24M | $4.82M | $77.88M | (m) | (m) | (m) | $885.00K | (m) | 16.45× |
| 2015-12-31 | $85.09M | $6.66M | $83.42M | (m) | (m) | (m) | $1.22M | (m) | 12.79× |
| 2015-09-30 | $62.61M | $8.12M | $59.75M | (m) | (m) | (m) | $549.00K | (m) | 7.71× |
| 2015-06-30 | $75.45M | $9.98M | $71.95M | (m) | (m) | (m) | $920.00K | (m) | 7.56× |
| 2015-03-31 | $90.62M | $10.95M | $88.26M | (m) | (m) | (m) | $1.13M | (m) | 8.28× |
| 2014-12-31 | $104.82M | $10.28M | $102.24M | (m) | (m) | (m) | $1.15M | (m) | 10.20× |
| 2014-09-30 | $82.58M | $8.50M | $79.09M | (m) | (m) | (m) | $696.00K | (m) | 9.72× |
| 2014-06-30 | $93.49M | $7.56M | $90.84M | (m) | (m) | (m) | $1.46M | (m) | 12.36× |
| 2014-03-31 | $52.26M | $8.63M | $46.04M | (m) | (m) | (m) | $1.32M | (m) | 6.05× |
| 2013-12-31 | $43.85M | $7.45M | $38.19M | (m) | (m) | (m) | $1.22M | (m) | 5.89× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B |